Stay up to date with FDA policies and adjust prescriptions accordingly
GLP-1 receptor agonists, by achieving greater weight loss than obtained with other medications, may represent a therapeutic opportunity for improving obesity in patients with PsO and HS, with resulting decrease in CVR and, in general, improvement in the medium to long term
As well, genetic factors such as genetic variations in TCF7L2 genes may influence how long your body takes to lose weight
Many patients remain on maintenance doses after reaching their goal weight to help prevent weight regain
Review semaglutide tips for optimizing the overall protocol at this stage
Safety Updates for Lamictal, Kineret, Miebo Eye Drops, Zoladex